Children's Oncology Group's 2013 blueprint for research: Neuroblastoma

Julie R. Park; Rochelle Bagatell; Wendy B. London; John M. Maris; Susan L. Cohn; Katherine M. Mattay; Michael Hogarty

doi:10.1002/pbc.24433

Children's Oncology Group's 2013 blueprint for research: Neuroblastoma

Julie R. Park, Rochelle Bagatell, Wendy B. London, John M. Maris, Susan L. Cohn, Katherine M. Mattay, Michael Hogarty

Research output: Contribution to journal › Review article › peer-review

262 Scopus citations

Abstract

Estimated 5-year survival rates for patients with non-high-risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non-high-risk disease. For patients with high-risk neuroblastoma treated with chemoradiotherapy, surgery, and stem cell transplantation, the addition of anti-disialoganglioside (GD2) immunotherapy plus cytokines improves survival. Upcoming trials will study the incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high-risk treatment. Phase 2 trials will investigate druggable target(s) including mTOR inhibition and GD2-directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK-aberrant tumors.

Original language	English
Pages (from-to)	985-993
Number of pages	9
Journal	Pediatric Blood and Cancer
Volume	60
Issue number	6
DOIs	https://doi.org/10.1002/pbc.24433
State	Published - Jun 2013
Externally published	Yes

Keywords

Children
Malignancies
Neuroblastoma

Access to Document

10.1002/pbc.24433

Cite this

@article{5707573826714d7a996b85d42a2b9892,

title = "Children's Oncology Group's 2013 blueprint for research: Neuroblastoma",

abstract = "Estimated 5-year survival rates for patients with non-high-risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non-high-risk disease. For patients with high-risk neuroblastoma treated with chemoradiotherapy, surgery, and stem cell transplantation, the addition of anti-disialoganglioside (GD2) immunotherapy plus cytokines improves survival. Upcoming trials will study the incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high-risk treatment. Phase 2 trials will investigate druggable target(s) including mTOR inhibition and GD2-directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK-aberrant tumors.",

keywords = "Children, Malignancies, Neuroblastoma",

author = "Park, {Julie R.} and Rochelle Bagatell and London, {Wendy B.} and Maris, {John M.} and Cohn, {Susan L.} and Mattay, {Katherine M.} and Michael Hogarty",

year = "2013",

month = jun,

doi = "10.1002/pbc.24433",

language = "English",

volume = "60",

pages = "985--993",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - Children's Oncology Group's 2013 blueprint for research

T2 - Neuroblastoma

AU - Park, Julie R.

AU - Bagatell, Rochelle

AU - London, Wendy B.

AU - Maris, John M.

AU - Cohn, Susan L.

AU - Mattay, Katherine M.

AU - Hogarty, Michael

PY - 2013/6

Y1 - 2013/6

N2 - Estimated 5-year survival rates for patients with non-high-risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non-high-risk disease. For patients with high-risk neuroblastoma treated with chemoradiotherapy, surgery, and stem cell transplantation, the addition of anti-disialoganglioside (GD2) immunotherapy plus cytokines improves survival. Upcoming trials will study the incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high-risk treatment. Phase 2 trials will investigate druggable target(s) including mTOR inhibition and GD2-directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK-aberrant tumors.

AB - Estimated 5-year survival rates for patients with non-high-risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non-high-risk disease. For patients with high-risk neuroblastoma treated with chemoradiotherapy, surgery, and stem cell transplantation, the addition of anti-disialoganglioside (GD2) immunotherapy plus cytokines improves survival. Upcoming trials will study the incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high-risk treatment. Phase 2 trials will investigate druggable target(s) including mTOR inhibition and GD2-directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK-aberrant tumors.

KW - Children

KW - Malignancies

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=84876430459&partnerID=8YFLogxK

U2 - 10.1002/pbc.24433

DO - 10.1002/pbc.24433

M3 - Review article

C2 - 23255319

AN - SCOPUS:84876430459

SN - 1545-5009

VL - 60

SP - 985

EP - 993

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 6

ER -

Children's Oncology Group's 2013 blueprint for research: Neuroblastoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this